Potential use of nanoencapsulated cannabinoids for the treatment of inflammatory bowel diseases: a systematic review
DOI:
https://doi.org/10.33448/rsd-v11i10.33011Keywords:
Inflammatory Bowel Disease; Cannabinoids; Cannabis sativa; Nanotechnology.Abstract
Introduction: Inflammatory Bowel Disease (IBD) are diseases characterized by intestinal inflammation, divided into Crohn's Disease (CD) and Ulcerative Retrocolitis (UC). The cause is still unknown. There are a variety of studies that show the beneficial and potential effect of phytocannabinoids on Inflammatory Bowel Disease. Objective: To evaluate the beneficial effect of Cannabis sativa-derived metabolites in the treatment of IBD, associated with the use of nanotechnology in order to enhance this effect, through a systematic review study. Methodology: This systematic review of the literature of pre-clinical and clinical trials was carried out in the following databases: PUBMED, Science Direct and Scopus from 2012 to 2022. Some combinations of terms were used, such as inflammatory bowel diseases, cannabinoids, cannabidiol and nanotechnology. Results: A total of 418 articles were found in Pubmed, 80 articles in Science Direct and 443 in Scopus. In the end, 6 articles in Pubmed, 10 in Science Direct and 6 in Scopus were considered eligible for analysis according to the established inclusion and exclusion criteria. Discussion: In the analyzed studies, it was noticed that phytocannabinoids represent a promising alternative to treat IBD. Despite the great expectations surrounding these molecules, their physicochemical characteristics represent a significant limitation for their application in the treatment of IBD and other diseases. Therefore, nanotechnology proved to be a way to overcome these problems. Conclusion: In view of all the above, it can be inferred that metabolites derived from Cannabis sativa have great potential for the treatment of inflammatory bowel diseases.
References
Ambrose, T., & Simmons, A. (2019). Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease? Journal of Crohn’s and Colitis, 13(4), 525–535.
Argollo, M., Fiorino, G., Hindryckx, P., Peyrin-Biroulet, L., & Danese, S. (2017). Novel therapeutic targets for inflammatory bowel disease. Journal of Autoimmunity, 85, 103–116.
Becker, W., Alrafas, H. R., Wilson, K., Miranda, K., Culpepper, C., Chatzistamou, I., & Nagarkatti, P. S. (2020). Activation of cannabinoid receptor 2 prevents colitis-associated colon cancer through myeloid cell de-activation upstream of IL-22 production. Iscience, 23(9), 101504.
Bogale, K., Raup-Konsavage, W., Dalessio, S., Vrana, K., & Coates, M. D. (2021). Cannabis and Cannabis Derivatives for Abdominal Pain Management in Inflammatory Bowel Disease. Medical Cannabis and Cannabinoids, 4(2), 97–106.
Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., & Izzo, A. A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical pharmacology, 85(9), 1306-1316.
Cocetta, V., Governa, P., Borgonetti, V., Tinazzi, M., Peron, G., Catanzaro, D., … Montopoli, M. (2021). Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress. Frontiers in Pharmacology, 12.
Couch, D. G., Cook, H., Ortori, C., Barrett, D., Lund, J. N., & O'Sullivan, S. E. (2019). Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflammatory bowel diseases, 25(6), 1006–1018. https://doi.org/10.1093/ibd/izz017
de Carvalho, A. C. A., de Souza, G. A., de Marqui, S. V., Guiguer, É. L., Araújo, A. C., Rubira, C. J., Goulart, R. de A., Flato, U. A. P., Bueno, P. C. D. S., Buchaim, R. L., & Barbalho, S. M. (2020). Cannabis and canabidinoids on the inflammatory bowel diseases: Going beyond misuse. International Journal of Molecular Sciences, 21(8). https://doi.org/10.3390/IJMS21082940
Dunford, J., Lee, A. T., & Morgan, M. M. (2021). Tetrahydrocannabinol (THC) Exacerbates Inflammatory Bowel Disease in Adolescent and Adult Female Rats. The journal of pain, 22(9), 1040-1047.
Fernandes, I., & Gil, L. (2019). Qualidade de vida da pessoa com doença inflamatória intestinal. Revista de Enfermagem Referência, IV Série(23), 89–98.
Guan, Q. (2019). A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. Journal of Immunology Research, 2019.
Harvey, B. S., Sia, T. C., Wattchow, D. A., & Smid, S. D. (2014). Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. Cytokine, 65(2), 236-244.
Hazel, K., & O’Connor, A. (2020). Emerging treatments for inflammatory bowel disease. Therapeutic Advances in Chronic Disease, 11. https://doi.org/10.1177/2040622319899297
Hoffenberg, E. J., McWilliams, S. K., Mikulich-Gilbertson, S. K., Murphy, B. V., Lagueux, M., Robbins, K., & Hopfer, C. J. (2018). Marijuana use by adolescents and young adults with inflammatory bowel disease. The Journal of pediatrics, 199, 99-105.
Hoffenberg, E. J., McWilliams, S., Mikulich-Gilbertson, S., Murphy, B., Hoffenberg, A., & Hopfer, C. J. (2019). Cannabis oil use by adolescents and young adults with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition, 68(3), 348–352.
Irving, P. M., Iqbal, T., Nwokolo, C., Subramanian, S., Bloom, S., Prasad, N., Hart, A., Murray, C., Lindsay, J. O., Taylor, A., Barron, R., & Wright, S. (2018). A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Inflammatory bowel diseases, 24(4), 714–724.
Kaplan, G. G., & Ng, S. C. (2017). Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology, 152(2), 313-321.e2.
Kienzl, M., Storr, M., & Schicho, R. (2020). Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. Clinical and Translational Gastroenterology, 11(1), e00120.
Martín-Banderas, L., Munoz-Rubio, I., Álvarez-Fuentes, J., Durán-Lobato, M., Arias, J. L., Holgado, M. Á., & Fernández-Arévalo, M. (2014). Engineering of Δ9-tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms. Colloids and Surfaces B: Biointerfaces, 123, 114-122.
Matarazzo, A. P., Elisei, L. M. S., Carvalho, F. C., Bonfílio, R., Ruela, A. L. M., Galdino, G., & Pereira, G. R. (2021). Mucoadhesive nanostructured lipid carriers as a cannabidiol nasal delivery system for the treatment of neuropathic pain. European Journal of Pharmaceutical Sciences, 159, 105698.
Moher D., Liberati A., Tetzlaff J., Altman D.G., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535
Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E. P., Sklerovsky Benjaminov, F., & Konikoff, F. M. (2013). Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 11(10), 1276–1280.e1.
Naftali, T., Bar-Lev Schleider, L., Scklerovsky Benjaminov, F., Konikoff, F. M., Matalon, S. T., & Ringel, Y. (2021). Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial. PloS one, 16(2), e0246871.
Naftali, T., Mechulam, R., Marii, A., Gabay, G., Stein, A., Bronshtain, M., Laish, I., Benjaminov, F., & Konikoff, F. M. (2017). Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial. Digestive diseases and sciences, 62(6), 1615–1620.
Nallathambi, R., Mazuz, M., Ion, A., Selvaraj, G., Weininger, S., Fridlender, M., … Koltai, H. (2017). Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts. Cannabis and Cannabinoid Research, 2(1), 167–182.
Pagano, E., Iannotti, F. A., Piscitelli, F., Romano, B., Lucariello, G., Venneri, T., … Borrelli, F. (2021). Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. Phytotherapy Research, 35(1), 517–529.
Pagano, E., Romano, B., Iannotti, F. A., Parisi, O. A., D’armiento, M., Pignatiello, S., & Borrelli, F. (2019). The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. Pharmacological Research, 149, 104464.
Perisetti, A., Rimu, A. H., Khan, S. A., Bansal, P., & Goyal, H. (2020). Role of cannabis in inflammatory bowel diseases. Annals of Gastroenterology, 33(2), 134–144.
Picardo, S., Kaplan, G. G., Sharkey, K. A., & Seow, C. H. (2019). Insights into the role of cannabis in the management of inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 12, 1–13.
Seyedian, S. S., Nokhostin, F., & Malamir, M. D. (2019). A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. Journal of Medicine and Life, 12(2), 113–122.
Silvestri, C., Pagano, E., Lacroix, S., Venneri, T., Cristiano, C., Calignano, A., … Borrelli, F. (2020). Fish Oil, Cannabidiol and the Gut Microbiota: An Investigation in a Murine Model of Colitis. Frontiers in Pharmacology, 11.
Singh, U. P., Singh, N. P., Singh, B., Price, R. L., Nagarkatti, M., & Nagarkatti, P. S. (2012). Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10 -/- mice by attenuating the activation of T cells and promoting their apoptosis. Toxicology and Applied Pharmacology, 258(2), 256–267.
Tartakover Matalon, S., Azar, S., Meiri, D., Hadar, R., Nemirovski, A., Abu Jabal, N., Konikoff, F. M., Drucker, L., Tam, J., & Naftali, T. (2021). Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption. Frontiers in endocrinology, 12, 685289.
Vasconcelos, R. S., Rocha, R. M., Souza, E. B., Rabelo, V., Amaral, S., & Eb, S. (2018). Qualidade de vida de pacientes com doença inflamatória intestinal : revisão integrativa. 1–7.
Wang, C., Cui, B., Sun, Y., Wang, C., & Guo, M. (2022). Preparation, stability, antioxidative property and in vitro release of cannabidiol (CBD) in zein-whey protein composite nanoparticles. LWT, 162, 113466.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Alda Cássia Alves da Silva; Camila Fortes Castelo Branco Magalhães; Giovanna Carvalho Sousa Silva; Gisele Cristine Araújo Nascimento; Lívio Cesar Cunha Nunes; Patrícia e Silva Alves; Hercilia Maria Lins Rolim
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
